Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 12.80 is 72% above its 1-year average of 7.45, near the high end of its 1-year range (4.01–12.80).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 12.80.
QUICK RATIO (ACID-TEST)
12.80
QUICK RATIO (ACID-TEST) AVG TTM
N/A
QUICK RATIO (ACID-TEST) AVG 3Y
N/A
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.99
median of 621 covered companies
CURRENT VS SECTOR MEDIAN
+328.00%
vs the sector median at left
Mobia Medical, Inc. Common Stock
Market Cap
$306.56M
Quick Ratio (Acid-Test)
12.80
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$300.59M
Quick Ratio (Acid-Test)
34.00
TTM Avg
44.34
3Y Avg
25.02
5Y Avg
19.51
Market Cap
$322.98M
Quick Ratio (Acid-Test)
2.44
TTM Avg
4.94
3Y Avg
7.05
5Y Avg
7.05
Market Cap
$320.09M
Quick Ratio (Acid-Test)
5.45
TTM Avg
6.76
3Y Avg
6.92
5Y Avg
7.12
Market Cap
$320.81M
Quick Ratio (Acid-Test)
5.79
TTM Avg
4.46
3Y Avg
8.92
5Y Avg
12.08
Market Cap
$289.60M
Quick Ratio (Acid-Test)
8.80
TTM Avg
4.55
3Y Avg
3.67
5Y Avg
2.92
Market Cap
$288.79M
Quick Ratio (Acid-Test)
4.69
TTM Avg
11.27
3Y Avg
11.27
5Y Avg
11.27
Market Cap
$286.20M
Quick Ratio (Acid-Test)
4.70
TTM Avg
5.10
3Y Avg
7.75
5Y Avg
8.34
Market Cap
$281.41M
Quick Ratio (Acid-Test)
31.35
TTM Avg
25.02
3Y Avg
20.04
5Y Avg
16.05
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mobia Medical, Inc. Common Stock (MOBI) | $306.56M | 12.80 | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $300.59M | 34.00 | 44.34 | 25.02 | 19.51 |
| CapsoVision, Inc. (CV)vs › | $322.98M | 2.44 | 4.94 | 7.05 | 7.05 |
| C4 Therapeutics, Inc. (CCCC)vs › | $320.09M | 5.45 | 6.76 | 6.92 | 7.12 |
| Cabaletta Bio, Inc. (CABA)vs › | $320.81M | 5.79 | 4.46 | 8.92 | 12.08 |
| Standard BioTools Inc. (LAB)vs › | $289.60M | 8.80 | 4.55 | 3.67 | 2.92 |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $288.79M | 4.69 | 11.27 | 11.27 | 11.27 |
| Larimar Therapeutics, Inc. (LRMR)vs › | $286.20M | 4.70 | 5.10 | 7.75 | 8.34 |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.41M | 31.35 | 25.02 | 20.04 | 16.05 |
| ClearPoint Neuro, Inc. (CLPT)vs › | $331.54M | 3.87 | 3.84 | 4.42 | 6.10 |
Quick Ratio
12.80
Excludes inventory
Current Ratio
13.28
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 12.80 |
| 2026-03-31 | 5.55 |
| 2025-12-31 | 4.01 |
